替吉奥分别联合紫杉醇或奥沙利铂一线治疗晚期胃癌的疗效及安全评价

Comparison of effects between fluorouracil combined with oxaliplatin and paclitaxel in the treatment of advanced gastric cancer

目的对比分析替吉奥联合奥沙利铂或紫杉醇对晚期胃癌的临床化疗效果及安全性分析。方法将晚期胃癌患者分为2组。A组予替吉奥40 mg/m^2联合奥沙利铂130 mg/m^2(n=49),B组予替吉奥40 mg/m^2联合紫杉醇150 mg/m^2(n=40)。结果化疗2个周期,A组缓解率(38.78%)稍高于B组(37.50%);化疗3个月后A组缓解率为51.02%,控制率为71.43%;B组缓解率为47.50%,控制率为75.00%。B组不良反应高于A组(P<0.05)。A组中位无进展生存期(PFS)为4.3个月,B组的中位PFS为3.9个月。结论与B组相比,A组短期缓解率更高,不良反应更少,无进展生存期稍长,两组化疗方案近期疗效差异无统计学意义。

Objective To compare the effects of oxaliplatin combined with fluorouracil with paclitaxel combined with fluorouracil in the treatment of advanced gastric cancer(AGC).Methods We selected 89 cases of patients with advanced gastric cancer and divided then into 2 groups,with least 3 months chemotherapy.The group A was treated with oxaliplatin 130 mg/m^2 combined with fluorouracil 40 mg/m^2.The Group B was treated with paclitaxel 135-175 mg/m^2 combined with fluorouracil 40 mg/m^2.Results The ORR of group A was 38.78%higher than that of group B 37.50%after two cycle of chemotherapy.After three chemotherapy,no differencs was found between group A(ORR 51.02%,DCR 71.43%)and group B(ORR 47.50%,DCR 75.00%).Adverse events of group A was less than group B(P<0.05).The median PFS of group A was 4.3 months,and the median PFS of group B was 3.9 months.The difference between the groups by Log-rank test was statistically significant.Conclusions After 3-month treatment no difference is found between oxaliplatin combined with fluorouracil and paclitaxel combined with fluorouracil,however the oxaliplatin combined with fluorouracil is showed higher frequence of short-term remission,and less adverse reactions.